SCHEDULE 13G/A: 3i LP Updates Significant Stake in CNBX Pharmaceuticals, Maintaining 9.9% Beneficial Ownership

3i, LP, along with its affiliates, has filed an Amendment No. 3 to its Schedule 13G, reaffirming its beneficial ownership of 9.9% of CNBX Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Summary

• 3i, LP, 3i Management LLC, and Maier Joshua Tarlow (collectively, the "Reporting Persons") have filed an Amendment No. 3 to their Schedule 13G for CNBX Pharmaceuticals Inc.
• The filing updates their beneficial ownership information, showing an aggregate beneficial ownership of 3,412,557 shares of CNBX Pharmaceuticals Inc. Common Stock.
• This represents 9.9% of the company's outstanding common stock, based on 31,111,352 shares outstanding as disclosed in CNBX's Quarterly Report on Form 10-Q for the fiscal period ended November 30, 2024.
• The beneficial ownership consists of 364,179 shares of Common Stock held directly by 3i, LP, and 3,048,378 shares issuable upon conversion of a senior secured convertible note (the "Note") held by 3i, LP.
• Conversion of the Note is subject to a 9.99% beneficial ownership limitation provision (the "Blocker"), preventing the holder from exceeding 9.99% ownership upon conversion.
• The Reporting Persons share both voting and dispositive power over all 3,412,557 beneficially owned shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing (Schedule 13G/A) disclosing beneficial ownership. It contains no operational or financial performance updates for the issuer, and the stated purpose of the ownership is passive, thus it is neutral in sentiment.

Positives

• The continued significant stake (9.9%) by 3i, LP, an institutional investor, may signal ongoing confidence in CNBX Pharmaceuticals Inc.
• The 9.99% beneficial ownership limitation (Blocker) on the convertible note provides a degree of protection against excessive immediate dilution from this specific investor.

Negatives

• No explicit negatives are detailed in this beneficial ownership disclosure.

Risks

• The existence of a senior secured convertible note means potential future dilution for existing shareholders if the note is converted into common stock, although currently limited by the 9.99% blocker.
• The 9.99% beneficial ownership limitation (Blocker) restricts 3i, LP's ability to convert more shares, potentially limiting their upside if the company's stock price significantly increases and they wish to increase their stake beyond the current threshold.

Future Outlook

The document does not provide forward-looking statements or guidance from CNBX Pharmaceuticals Inc. It primarily details the current beneficial ownership stake of the Reporting Persons and their passive investment intent.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Maier Joshua Tarlow on behalf of Reporting Persons)

Industry Context

This filing is a routine disclosure of a significant ownership stake by an institutional investor in a pharmaceutical company. It does not provide specific insights into broader industry trends but confirms ongoing investment activity within the sector.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake and the potential for future dilution from the conversion of the senior secured convertible note, albeit limited by a blocker provision.

Key Dates

Keywords

CNBX Pharmaceuticals Inc., Schedule 13G, beneficial ownership, 3i LP, convertible note, institutional investor, common stock, SEC filing, ownership update